| Code | CSB-RA004929MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to FTL004, targeting CD38 (Cluster of Differentiation 38), a type II transmembrane glycoprotein with both receptor and ectoenzyme functions. CD38 catalyzes the synthesis and hydrolysis of cyclic ADP-ribose and ADP-ribose from NAD+, playing crucial roles in calcium signaling, cell adhesion, and signal transduction. This protein is widely expressed on immune cells including plasma cells, activated T cells, B cells, and natural killer cells. CD38 has emerged as a significant marker in hematological malignancies, particularly multiple myeloma, where it shows high expression on malignant plasma cells, making it a valuable therapeutic target and diagnostic marker.
FTL004 serves as a reference antibody in CD38 research, providing a validated tool for investigating CD38 biology and its involvement in immune regulation and cancer pathogenesis. This biosimilar antibody enables researchers to explore CD38-mediated pathways, evaluate its role in disease progression, and support preclinical studies in oncology and immunology research settings.
There are currently no reviews for this product.